Lung Cancer
Volume 62, Issue 1 , Pages 139-144 , October 2008

Predictors of talc pleurodesis outcome in patients with malignant pleural effusions

  • Huseyin Yildirim

      Affiliations

    • Osmangazi University, Medical Faculty, Department of Chest Disease, 26480 Meselik, Eskisehir, Turkey
    • Corresponding Author InformationCorresponding author. Tel.: +90 222 239 29 79x3050; fax: +90 222 239 47 14.
    • ,
  • Muzaffer Metintas

      Affiliations

    • Osmangazi University, Medical Faculty, Department of Chest Disease, 26480 Meselik, Eskisehir, Turkey
    • ,
  • Güntülü Ak

      Affiliations

    • Osmangazi University, Medical Faculty, Department of Chest Disease, 26480 Meselik, Eskisehir, Turkey
    • ,
  • Selma Metintas

      Affiliations

    • Osmangazi University, Medical Faculty, Department of Public Health, Eskisehir, Turkey
    • ,
  • Sinan Erginel

      Affiliations

    • Osmangazi University, Medical Faculty, Department of Chest Disease, 26480 Meselik, Eskisehir, Turkey

Received 17 December 2007 ,Revised 18 February 2008 ,Accepted 24 February 2008.

References 

  1. Antony VB, Loddenkemper R, Astoul P, Boutin C, Goldstraw P, Hott J, et al. Management of malignant pleural effusions. Eur Respir J. 2001;18:402–419
  2. Pleural Disease Group, Standards of Care Committee, British Thoracic Society. BTS guidelines for the management of malignant pleural effusions. Thorax. 2003;58:ii29
  3. Rodriguez-Panadero F, Antony VB. Therapeutic local procedures: pleurodesis. In:  Loddenkemper R,  Antony VB editor. Pleural diseases. Leeds: ERS Journals Ltd.; 2002;p. 311–326
  4. Sahn SA. Pleural disease related to metastatic malignancies. Eur Respir J. 1997;10:1907–1913
  5. Rodriguez-Panadero F, Antony VB. Pleurodesis: state of art. Eur Respir J. 1997;10:1648–1654
  6. Giusti G, Galanti B. Adenosine deaminase. In:  Bergmeyer HV editors. Methods of enzyme analysis. New York, NY: Academic Press; 1983;
  7. Dresler CM, Olak J, Herndon JE, Richards WG, Scalzetti E, Fleishman SB, et al. Phase III intergroup study of talc poudrage vs talc slurry sclerosis for malignant pleural effusion. Chest. 2005;127:909–915
  8. Psathakis K, Calderon-Osuna E, Romero-Romero B, Martin-Juan J, Romero-Falcon A, Rodriguez-Panadero F. The neutrophilic and fibrinolytic response to talc can predict the outcome of pleurodesis. Eur Respir J. 2006;27:817–821
  9. Burrows CM, Mathews C, Colt HG. Predicting survival in patients with recurrent symptomatic malignant pleural effusions: an assessment of the prognostic values of physiologic, morphologic, and qualify of life measures of extent of disease. Chest. 2000;117:73–78
  10. Martinez-Moragon E, Aparicio J, Sanchis J, Menedez R, Cruz Rogado M, Sanchis F. Malignant pleural effusion: prognostic factors for survival and response to chemical pleurodesis in a series of 120 cases. Respiration. 1998;65:108–113
  11. Aelony Y, King RR, Boutin C. Thoracoscopic talc poudrage in malignant pleural effusions: effective pleurodesis despite low pleural pH. Chest. 1998;113:1007–1012
  12. Heffner JE, Nietert PJ, Barbieri C. Pleural fluid pH as a predictor of pleurodesis failure—analysis of primary data. Chest. 2000;117:87–95
  13. Goodman A, Davies CVH. Efficacy of short term versus long term chest tube drainage following talc slurry pleurodesis in patients with malignant pleural effusions; a randomised trial. Lung Cancer. 2006;54:51–55
  14. Mager HJ, Maesen B, Verzijlbergen F, Schramel F. Distribution of talc suspension during treatment of malignant pleural effusion with talc pleurodesis. Lung Cancer. 2002;36:77–81

☆ This study has been presented as a thematic poster at the 14th Annual Congress of European Respiratory Society.

PII: S0169-5002(08)00105-0

doi: 10.1016/j.lungcan.2008.02.017

Lung Cancer
Volume 62, Issue 1 , Pages 139-144 , October 2008

Article Tools

* Image Usage & Resolution